New concepts in atrial defibrillation.
External cardioversion of AF is an established and accepted method for termination of individual episodes of AF. Recent advances have taken place in the area of non-pharmacologic management of AF, and despite its long history and well established technique, defibrillation has not been spared from these advances. The success of low-energy internal atrial defibrillation for the termination of both chronic and acute onset atrial fibrillation has resulted in the development of implantable defibrillators that treat this arrhythmia. Many of the advances have come about as a result of the use of defibrillation in implanted devices for recurrent AF due to the substantial efforts in an attempt to make this form of restoration of sinus rhythm more efficacious and tolerable to the patient. Additionally, the use of other non-pharmacologic control of atrial fibrillation has also been recently explored, namely the use of ablation and atrial pacing. The use of these other non-pharmacologic therapies are likely to both reduce the recurrence rate, as well as enhance the efficacy of defibrillation. However, defibrillation is likely to still be needed to terminate atrial fibrillation for persistent episodes, and its combination with these other therapies is likely synergistic. Electrical therapy to restore sinus rhythm for persistent episodes of atrial fibrillation is likely to be perceived by the patient. Therefore, the concept of patient controlled therapy from implanted devices to treat atrial fibrillation has shown promising results and will likely be a requirement of such devices in the future. Major advances in defibrillation therapy for atrial fibrillation have been made and have resulted in the development of implantable atrial defibrillators. Despite these advances in defibrillation and other therapies for atrial fibrillation, it is likely that combined pharmacologic and non-pharmacologic therapies for atrial fibrillation will prevail over the individual entities themselves. Future study is needed to determine the best therapy or combination of therapies for individual patients with atrial fibrillation.
Ayers
G M
GM
Corvascular Inc., Palo Alto, CA 94306, USA. gayers@corvascular.com.
D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage*; D001281:Atrial Fibrillation / Q000401:mortality / Q000628:therapy*; D017115:Catheter Ablation / Q000379:methods*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D004554:Electric Countershock / Q000379:methods*; D005260:Female; D006801:Humans; D008297:Male; D011379:Prognosis; D015996:Survival Rate; D016896:Treatment Outcome
D000889:Anti-Arrhythmia Agents